Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021983 · ClinicalTrials.gov registry record · Phase 1
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00021983: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00021983 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021983, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: An immunotoxin can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia. PURPOSE: Phase I trial to study the effectiveness of BL22 immunotoxin in treating patients who have refractory or recurrent hairy cell leukemia.
Interventions
- BIOLOGICAL BL22 immunotoxin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-12 |
| Phase | Phase 1 |
What the finished NCT00021983 record still lists
NCT00021983 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which BL22 immunotoxin is the first listed.
NCT00021983 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00021983 about?
NCT00021983 is a clinical study titled "Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia". RATIONALE: An immunotoxin can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia. PURPOSE: Phase I trial to study the effectiveness of BL22 immunotoxin in treating patients who have refractory or recurrent hairy cell leukemia.
What is the current status of trial NCT00021983?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-12.
What interventions are being tested in trial NCT00021983?
The interventions under investigation include: BL22 immunotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00021983?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia